Summary
Definição
História e exame físico
Principais fatores diagnósticos
- exertional dyspnea
Outros fatores diagnósticos
- orthopnea
- paroxysmal nocturnal dyspnea
- abdominal fullness
- rales
- jugular venous distention
- hepatojugular reflux
- congestive hepatomegaly
- lower extremity edema
- laterally displaced apical impulse
- gallop sounds
Fatores de risco
- hypertension
- atrial fibrillation (AF)
- female sex
- age >70 years
- obesity
- coronary artery disease (CAD)/ischemia
- diabetes mellitus
- chronic kidney disease (CKD)
- dyslipidemia
- exposure to cardiotoxic agents
- metabolic syndrome or cardiovascular-kidney-metabolic (CKM) syndrome
- myocardial and pericardial disorders
- obstructive sleep apnea
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- serum electrolytes
- renal function tests
- liver enzymes
- B-natriuretic peptide (BNP)/N-terminal prohormone B-natriuretic peptide (NT-proBNP)
- CBC and iron studies
- 12-lead ECG
- blood glucose
- thyroid function tests
- blood lipids
- CXR
- transthoracic echocardiography
Investigações a serem consideradas
- cardiac magnetic resonance (CMR) imaging
- CT angiography
- radionuclide ventriculography (MUGA scan)
- stress testing
- cardiopulmonary exercise testing (CPET)
- cardiac catheterization and coronary angiography
Algoritmo de tratamento
all patients
Colaboradores
Autores
Syed Wamique Yusuf, FACC, FRCPI
Professor of Medicine
Department of Cardiology
University of Texas MD Anderson Cancer Center
Houston
TX
Declarações
SWY declares that he has no competing interests.
Carl Zehner, MD
Assistant Professor of Medicine
Department of Cardiology
University of Texas MD Anderson Cancer Center
Houston
TX
Declarações
CZ declares that he has no competing interests.
Agradecimentos
Dr Syed Wamique Yusuf and Dr Carl Zehner would like to gratefully acknowledge Dr Gerald Carr-White, Dr Jessica Webb, Dr Gerard Aurigemma, Dr Lokesh Tejwani, Dr Marc E. Del Rosario, and Dr Kul Aggarwal, previous contributors to this topic.
Declarações
GCW has been reimbursed by Pfizer, AstraZeneca, Bayer, Medtronic, St Jude, and Sanofi for attending conferences. He has attended Advisory Boards for Medtronic, St Jude, Novartis, Shire, Sanofi, and Servier. JW has a joint working venture with BI for a community pharmacist post. GA, LT, MEDR, and KA declare that they have no competing interests.
Revisores
Edward Geltman, MD
Professor of Medicine
Cardiovascular Division
Washington University School of Medicine
St. Louis
MO
Declarações
EG has lectured for Novartis, Forest, Merck, and Pfizer.
Jerry Murphy, MB, BS, DM, FRCP
Consultant Cardiologist
Darlington Memorial Hospital
Darlington
UK
Раскрытие информации
Not disclosed.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Список литературы
Основные статьи
Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. 2021 Mar 1;S1071-9164(21)00050-6.Полный текст Аннотация
Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 May 9;81(18):1835-78.Полный текст Аннотация
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022 May 3;145(18):e895-1032.Полный текст Аннотация
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.Полный текст
McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.Полный текст
Borlaug BA, Sharma K, Shah SJ, et al. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023 May 9;81(18):1810-34. Аннотация
Статьи, указанные как источники
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Отличия
- Heart failure with reduced ejection fraction
- Cardiac amyloidosis
- Hypertrophic cardiomyopathy (HCM)
Больше ОтличияРекомендации
- 2024 ACC expert consensus decision pathway on clinical assessment, management, and trajectory of patients hospitalized with heart failure focused update: a report of the American College of Cardiology Solution Set Oversight Committee
- ACR appropriateness criteria: suspected and known heart failure
Больше РекомендацииЛифлеты для пациента
Heart failure
Heart failure: how can I help myself?
Больше Лифлеты для пациентаВойдите в учетную запись или оформите подписку, чтобы получить полноценный доступ к BMJ Best Practice
Использование этого контента попадает под действие нашего заявления об отказе от ответственности